Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus

Fig. 1

sSIGLEC-1 stability and assay performance. a Data depict the inter-assay (technical) variation of the time-resolved fluorescence (TRF) sSIGLEC-1 immunoassay. Data were obtained from the measurement of the same plasma sample from 23 healthy donors on two independent assays, performed 308 days apart. b Data depict the intra-individual (biological) variation of sSIGLEC-1 concentration between two visits of the same donor. Longitudinal variation was assessed in 19 independent healthy donors using plasma samples collected at each separate visit. Median time between visits was 378 days (minimum = 239 days, maximum = 519 days). c Technical variation of the electrochemical luminescence (ECL) sSIGLEC-1 immunoassay using the Meso Scale Discovery (MSD) platform. Assay stability was assessed in three reference quality control (QC) pools of serum samples with increasing sSIGLEC-1 concentrations (QC1 = 6.0 ng/ml, QC2 = 29.2 ng/ml and QC3 = 123.9 ng/ml), measured in each assay over a 2-day period. d Correlation between TRF (DELFIA) and ECL (MSD)-based immunoassays. Measurements were performed in independent serum aliquots from a subset of 41 SLE patients from cohort 3. P values were calculated by linear regression. CV coefficient of variation, DELFIA dissociation-enhanced lanthanide fluorescent immunoassay, sSIGLEC-1 soluble sialic acid binding Ig-like lectin 1

Back to article page